ROCKVILLE, Md., Sept. 17 /PRNewswire/ -- Adlyfe, a private company developing novel diagnostic testing technologies for early targets of amyloid diseases, announced today that it has appointed Roxanne Duan, Ph.D. as Vice President of Research. Dr. Duan will be responsible for overseeing the Adlyfe's Research efforts and will report directly to the Chief Executive Officer.
Duan comes to Adlyfe with nearly two decades of experience. Most recently, Dr. Duan served as Vice President of Research at Functional Genetics, Inc., where she made major impact on developing antibody therapeutics for infectious diseases and improving a gene perturbation technology that facilitated drug target discovery and validation. Prior to Functional Genetics, Dr. Duan was the project leader and co-inventor of several clinical protein therapeutic candidates at Human Genome Sciences (HGS), covering areas of cardiovascular diseases, wound repair, and diabetes. In addition, she holds more than 20 issued patents in the area of protein therapeutics and more than 25 peer reviewed publications.
Dr. Duan began her career as a Senior Research Fellow at the National Cancer Institute where she studied tumor suppressor genes. She received her B.Sc. in Pharmacy from National Taiwan University and her Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco and worked as a postdoctoral fellow at the Howard Hughes Medical Research Institute at the University of California, San Francisco, on growth factors and their application in cardiovascular diseases.
Alan Rudolph, President and CEO of Adlyfe, said, "We are delighted that
Roxanne has joined Adlyfe in this important new role. Her experience brings
a critical skill set to our rapidly growing diagnostic product development
activities. Her experience in protein biochemistry and development of
protein based assays be instrumental to our efforts to develop diagnostic
assays for neurodegenerative diseases such
'/>"/>
| SOURCE Adlyfe Copyright©2007 PR Newswire. All rights reserved |